outcomes of non-intensive chemotherapy differ for idh1 and idh2-mutated aml
Published 1 month ago • 57 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
3:23
the prognostic value of idh1 and idh2 in acute myeloid leukemia (aml)
-
4:31
limitations of targeted therapy for aml
-
1:39
optimizing chemotherapy in aml
-
2:07
the importance of induction chemotherapy in the aml treatment
-
2:00
flt3-itd-specific mrd predicts outcomes of chemotherapy in aml
-
2:22
session highlights: idh inhibitors, salvage regimens, and other novel developments in aml
-
1:42
novel treatment combinations in aml: what’s to come?
-
4:10
explore idh mutations
-
14:03
the 5 side effects of chemotherapy | acute myeloid leukaemia | aml | cancer |
-
2:19
acute myeloid leukemia - causes, symptoms, treatments & more…
-
0:50
update on the pimms trial of ivosidenib for patients with idh1-mutated ccus
-
3:03
improving aml outcomes
-
1:22
unanswered questions in aml: classification, the role of chemotherapy & avoiding relapse
-
1:40
intensive chemotherapy for aml: do we still need it?
-
1:10
novel methods to assess the effectiveness of chemotherapy in aml patients: mrd
-
5:35
venetoclax plus hmas in idh-mutant aml
-
1:41
the importance of integrating genomic and cytogenetic data in treatment decisions for aml
-
1:48
overall survival by idh2 mutant allele in late-stage r/r aml patients enrolled in idhentify
-
6:35
understanding aml
-
2:11
assessing untreated aml patients who are ineligible for intensive chemotherapy
-
1:48
idh1 inhibitor ivosidenib for the treatment of relapsed/ refractory aml
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma